Document Detail

Attenuation of edema and infarct volume following focal cerebral ischemia by early but not delayed administration of a novel small molecule KDR kinase inhibitor.
MedLine Citation:
PMID:  18951929     Owner:  NLM     Status:  MEDLINE    
Vascular endothelial growth factor (VEGF) may mediate increases in vascular permeability and hence plasma extravasation and edema following cerebral ischemia. To better define the role of VEGF in edema, we examined the effectiveness of a novel small molecule KDR kinase inhibitor Compound-1 in reducing edema and infarct volume following focal cerebral ischemia in studies utilizing treatment regimens initiated both pre- and post-ischemia, and with study durations of 24-72 h. Rats were subjected to 90 min of middle cerebral artery occlusion (MCAO) followed by reperfusion. Pretreatment with Compound-1 (40 mg/kg p.o.) starting 0.5h before occlusion significantly reduced infarct volume at 72 h post-MCAO (vehicle, 194.1+/-22.9 mm(3) vs. Compound-1, 127.6+/-22.8mm(3) and positive control MK-801, 104.4+/-22.6mm(3), both p<0.05 compared to vehicle control), whereas Compound-1 treatment initiated at 2h after occlusion did not affect infarct volume. Compound-1 pretreatment also significantly reduced brain water content at 24h (vehicle, 80.3+/-0.2% vs. Compound-1, 79.7+/-0.2%, p<0.05) but not at 72 h after MCAO. These results demonstrate that early pretreatment administration of a KDR kinase inhibitor elicited an early, transient decrease in edema and subsequent reduction in infarct volume, implicating VEGF as a mediator of stroke-related vascular permeability and ischemic injury.
Kelley A Foster; Hillary K Regan; Andrew P Danziger; Theodore Detwiler; Nancy Kwon; Keith Rickert; Joseph J Lynch; Christopher P Regan
Related Documents :
20236669 - Exacerbation of systemic inflammation and increased cerebral infarct volume with cardio...
17572859 - Bilateral near infrared spectroscopy in space-occupying middle cerebral artery stroke.
23187879 - Serum levels of γ-glutamyltransferase and progression of coronary atherosclerosis.
10705649 - Border zone neovascularization in cerebral ischemic infarct.
17961519 - Neuroprotection by neuregulin-1 in a rat model of permanent focal cerebral ischemia.
10978029 - Atherothrombotic middle cerebral artery territory infarction: topographic diversity wit...
15737219 - Acute coronary syndromes: cardiac rehabilitation programmes and quality of life.
8983669 - The renin-angiotensin system and the heart: beyond 2000.
23737229 - Disease management: remote monitoring in heart failure patients with implantable defibr...
Publication Detail:
Type:  Journal Article     Date:  2008-10-04
Journal Detail:
Title:  Neuroscience research     Volume:  63     ISSN:  0168-0102     ISO Abbreviation:  Neurosci. Res.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-22     Completed Date:  2009-04-20     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  8500749     Medline TA:  Neurosci Res     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  10-6     Citation Subset:  IM    
Department of Schizophrenia Research, Merck Research Laboratories, West Point, PA 19486, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Brain / drug effects,  enzymology,  physiopathology
Brain Edema / drug therapy*,  enzymology,  physiopathology
Cerebral Infarction / drug therapy*,  enzymology,  physiopathology
Disease Models, Animal
Drug Administration Schedule
Enzyme Inhibitors / chemistry,  therapeutic use*
Hypoxia-Ischemia, Brain / drug therapy*,  enzymology,  physiopathology
Indoles / chemistry,  therapeutic use*
Infarction, Middle Cerebral Artery / drug therapy,  enzymology,  physiopathology
Molecular Weight
Piperazines / chemistry,  therapeutic use*
Time Factors
Treatment Outcome
Vascular Endothelial Growth Factor A / metabolism
Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors*,  metabolism
Reg. No./Substance:
0/3-(5-((4-(methylsulfonyl)-1-piperazinyl)methyl)-1H-indole-2-yl)quinolin-2(1H)-one; 0/Enzyme Inhibitors; 0/Indoles; 0/Piperazines; 0/Vascular Endothelial Growth Factor A; EC Endothelial Growth Factor Receptor-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intracellular zinc increase inhibits p53(-/-) pancreatic adenocarcinoma cell growth by ROS/AIF-media...
Next Document:  AP-1 and ERK1 but not p38 nor JNK is required for CRPV early protein 2-dependent MMP-9 promoter acti...